Cardiac vagal activity is associated with insulin metabolism in heart failure : results from the Myovasc study
| dc.contributor.author | Bélanger, Noémie | |
| dc.contributor.author | Zeid, Silav | |
| dc.contributor.author | Velmeden, David | |
| dc.contributor.author | Schulz, Andreas | |
| dc.contributor.author | Koeck, Thomas | |
| dc.contributor.author | Rausch, Felix | |
| dc.contributor.author | Fooß, Benedikt | |
| dc.contributor.author | Kazemi-Asrar, Fawad | |
| dc.contributor.author | Lackner, Karl J. | |
| dc.contributor.author | Gori, Tommaso | |
| dc.contributor.author | Münzel, Thomas | |
| dc.contributor.author | Prochaska, Jürgen H. | |
| dc.contributor.author | Simon, Perikles | |
| dc.contributor.author | Wild, Philipp S. | |
| dc.date.accessioned | 2026-06-16T09:00:14Z | |
| dc.date.issued | 2026 | |
| dc.description.abstract | Background Cardiac autonomic dysfunction plays a pivotal role in the heart failure syndrome. Metabolic dysregulation affects both autonomic function and heart failure, but these relationships remain incompletely understood. This study aimed at investigating the role of glucose and insulin metabolism for parasympathetic reactivation. Methods Data from the MyoVasc study (NCT04064450), a prospective heart failure cohort study, were analyzed. Participants underwent a highly standardized 5-hour examination, including venous blood sampling. To assess the impact of glucose and insulin metabolism (HbA1c, HOMA-IR, and C-peptide) on parasympathetic reactivation as reflected by heart rate recovery 60 s (HRR60) after cardiopulmonary exercise testing, multivariable linear regression models with adjustment for sex, age, clinical profile (cardiovascular risk factors and comorbidities) and medication were calculated in cross-sectional and longitudinal settings. Additional adjustment for complementary glucose or insulin status was performed to assess the dependency of each other. Analyses were carried out in symptomatic heart failure and across the spectrum of glucose metabolism dysfunction. Results The analysis sample included 1,588 individuals (median age 64.0 years [IQR 55.0;72.0]; 33% women) in a fasting state. Symptomatic heart failure was present in 43.7% of the subjects. Median HRR60 was 21.0 beats per minute (IQR 14.0;28.0). In multivariable regression analysis with adjustment for age, sex, clinical profile, and medication, both HbA1c (βper SD −0.074, 95% CI [− 0.122;−0.026], P = 0.003) and HOMA-IR (βper SD −0.113 [− 0.165;−0.062], P < 0.0001) predicted HRR60. Additional adjustment for both glucose and insulin status, respectively, demonstrated that HOMA-IR (βper SD −0.097 [− 0.155;−0.040], P < 0.0001), but not HbA1c (βper SD −0.030 [− 0.084;0.025], P = 0.28), was independently related to HRR60. This finding was confirmed in subgroups with heart failure and type 2 diabetes. In all analyses, C-peptide was related to HRR60 independently of HbA1c with higher effect estimates than HOMA-IR (βper SD −0.171 [− 0.225;−0.117], P < 0.0001). Finally, higher HbA1c (βper SD −0.094, [− 0.171;−0.017], P = 0.017) and C-peptide (βper SD −0.076, [− 0.159;0.007], P = 0.075) were more strongly associated with a lower HRR60 after two years of follow-up. Conclusions This study demonstrates the relevance of insulin status for vagal activity of cardiac autonomic function, particularly in heart failure. The pathophysiological implications underlying the relationship between insulin status and parasympathetic activity merit further mechanistic exploration. | |
| dc.identifier.doi | https://doi.org/10.25358/openscience-15487 | |
| dc.identifier.uri | https://openscience.ub.uni-mainz.de/handle/20.500.12030/15508 | |
| dc.language.iso | eng | |
| dc.rights | CC-BY-4.0 | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
| dc.subject.ddc | 610 Medizin | de |
| dc.subject.ddc | 610 Medical sciences | en |
| dc.title | Cardiac vagal activity is associated with insulin metabolism in heart failure : results from the Myovasc study | en |
| dc.type | Zeitschriftenaufsatz | |
| jgu.apc.netprice | 2441,85 | |
| jgu.apc.price | 2612,78 | |
| jgu.apc.taxrate | 7 | |
| jgu.apc.transformationcontract | Springer (DEAL) | |
| jgu.dfg.year | 2026 | |
| jgu.identifier.uuid | c00bd8ac-af65-4c4a-bef8-1d64ce357c48 | |
| jgu.journal.title | Cardiovascular diabetology | |
| jgu.journal.volume | 25 | |
| jgu.nationalcurrency.eur | 2441,85 | |
| jgu.notes.public | Thomas Münzel wird fälschlicherweise in der Publikation unter dem Namen Tommaso Münzel aufgeführt. | |
| jgu.organisation.department | FB 04 Medizin | |
| jgu.organisation.name | Johannes Gutenberg-Universität Mainz | |
| jgu.organisation.number | 2700 | |
| jgu.organisation.place | Mainz | |
| jgu.organisation.ror | https://ror.org/023b0x485 | |
| jgu.pages.alternative | 26 | |
| jgu.publisher.doi | 10.1186/s12933-025-03040-9 | |
| jgu.publisher.eissn | 1475-2840 | |
| jgu.publisher.name | BioMed Central | |
| jgu.publisher.place | London | |
| jgu.publisher.year | 2026 | |
| jgu.rights.accessrights | openAccess | |
| jgu.subject.ddccode | 610 | |
| jgu.subject.dfg | Lebenswissenschaften | |
| jgu.type.contenttype | Scientific article | |
| jgu.type.dinitype | Article | en_GB |
| jgu.type.resource | Text | |
| jgu.type.version | Published version |